Beyond 30 days, Meir et al. reported the incidence of any grade infections/febrile neutropenia in pivotal trials for CD19 CAR-T therapies ranging from 32-43% (any grade) (3-13% grade ≥ 3) for NHL and ALL.13 Here, CD19 is linked to non-Hodgkin lymphoma.